Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?

Summary

Article discusses Mineralys Therapeutics and its drug lorundrostat's potential in cardiovascular applications. No specific clinical data, regulatory events, or financial information is provided in the headline.